Skip to main content
. 2020 Dec 15;12(12):8162–8174.

Figure 2.

Figure 2

SOX12 promotes breast cancer progression. A. Comparison of the proportions of positive SOX12 expression of adjacent normal tissues (ANTs), ductal carcinoma in situ (DCIS), invasive carcinoma without lymph node metastasis (ICW), and invasive carcinoma with lymph node metastasis (ICLNM) tissues. Gradual increases in SOX12 expression levels with breast cancer progression. B. Markedly increased median immunoreactive score (IRS) with breast cancer progression. C. Representative SOX12 immunohistochemistry (IHC) staining micrographs of ANTs, DCIS, ICW, and ICLNM. Increased staining intensities in invasive carcinoma tissues. D. Higher median IRS in invasive carcinoma (IC) than in DCIS under the same estrogen receptor (ER) status. E. Comparison of the percentages of positive SOX12 expression in TNM stages I, II, and III. Gradual increases in the proportion of positive SOX12 expression as the cancer progresses. F. Increase in median SOX12 IRS as the extent of cancer increases. G. Representative SOX12 staining micrographs of stages I, II, and III.